We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Leucine Supplementation in Elderly Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00807508
Recruitment Status : Completed
First Posted : December 12, 2008
Last Update Posted : December 12, 2008
Sponsor:
Information provided by:

Study Description
Brief Summary:
In the present study the investigators aim to determine whether leucine supplementation can augment muscle mass and strength and improve body composition in healthy elderly men

Condition or disease Intervention/treatment Phase
Sarcopenia Atrophy Aging Dietary Supplement: placebo Dietary Supplement: leucine Phase 1 Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Influence of Leucine Supplementation on Body Composition and Muscle Characteristics in Healthy Elderly
Study Start Date : January 2007
Primary Completion Date : December 2007
Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Leucine
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
daily leucine supplementation
Dietary Supplement: leucine
daily leucine capsules with each main meal
Placebo Comparator: 2
daily placebo supplementation
Dietary Supplement: placebo
wheat meal capsules with each main meal


Outcome Measures

Primary Outcome Measures :
  1. muscle mass and body composition [ Time Frame: before and after 12 wk intervention ]

Secondary Outcome Measures :
  1. muscle strength [ Time Frame: before and after 12 wk intervention ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • living independently

Exclusion Criteria:

  • Diabetes cardiovascular disease orthopedic limitations history of resistance training in past 5 years
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00807508


Locations
Netherlands
Maastricht University Medical Centre
Maastricht, Netherlands, 6200 MD
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Principal Investigator: Luc JC van Loon, PhD Maastricht University Medical Center
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Luc JC van Loon, PhD, MaastrichtUMC
ClinicalTrials.gov Identifier: NCT00807508     History of Changes
Other Study ID Numbers: MEC 06-3-062A
First Posted: December 12, 2008    Key Record Dates
Last Update Posted: December 12, 2008
Last Verified: December 2008

Additional relevant MeSH terms:
Atrophy
Sarcopenia
Pathological Conditions, Anatomical
Muscular Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms